An individual-patient meta-analysis sheds light on the optimal duration of androgen deprivation therapy in men with prostate cancer on definitive radiotherapy.
News Medical on MSN
New trial tests strategies to protect heart health during prostate cancer therapy
City of Hope ® , one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation's top cancer centers by ...
Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.
Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...
Multimodal treatment including radical prostatectomy might lead to improved survival in patients with oligometastatic prostate cancer treated with ADT. Men with oligometastatic prostate cancer (OmPCa) ...
Results from the pivotal Phase III ARANOTE trial evaluating darolutamide plus androgen deprivation therapy (ADT) showed a statistically significant increase in radiological progression-free survival ...
Consistent benefits in radiological progression-free survival were observed across patient subgroups. An analysis of immature data of overall survival suggested potential benefit with darolutamide ...
In North American studies, heart failure risk appeared to be lower among patients receiving ADT than it was for the overall analysis, whereas the risk with ADT across Asian studies was higher. The use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results